本文通过对三义黄土剖面孢粉资料的分析,初步重建了内蒙克旗地区16000 a以来植被及环境的变迁过程.约16 010～15 380 aBP,植被稀疏,气候寒冷而干燥;约15 380～11270 a B P,植被以草本植物为主,气候变得更加干旱;约11270～9 940 a B P,...本文通过对三义黄土剖面孢粉资料的分析,初步重建了内蒙克旗地区16000 a以来植被及环境的变迁过程.约16 010～15 380 aBP,植被稀疏,气候寒冷而干燥;约15 380～11270 a B P,植被以草本植物为主,气候变得更加干旱;约11270～9 940 a B P,气候总体上由先前的冷干开始向暖湿方向发展,植被仍以草原为主;约9 940～2 320 a B P,植被得到进一步发展,气候表现出温暖湿润的特征;约2 320 a B P至今,植被仍以草原为主,气候向温凉方向发展.展开更多
By 2050 the prevalence of diabetes will more than triple globally,dramatically increasing the societal and financial burden of this disease worldwide.As a consequence of this growth,it is anticipated that there will b...By 2050 the prevalence of diabetes will more than triple globally,dramatically increasing the societal and financial burden of this disease worldwide.As a consequence of this growth,it is anticipated that there will be a concurrent rise in the numbers of patients with diabetic macular edema(DME),already among the most common causes of severe vision loss worldwide.Recent available therapies for DME target the secreted cytokine,vascular endothelial growth factor(VEGF).This review focuses on the treatment of DME using the first humanized monoclonal antibody targeting VEGF that has been Food and Drug Administrationapproved for the use in the eye,ranibizumab(Lucentis).展开更多
文摘本文通过对三义黄土剖面孢粉资料的分析,初步重建了内蒙克旗地区16000 a以来植被及环境的变迁过程.约16 010～15 380 aBP,植被稀疏,气候寒冷而干燥;约15 380～11270 a B P,植被以草本植物为主,气候变得更加干旱;约11270～9 940 a B P,气候总体上由先前的冷干开始向暖湿方向发展,植被仍以草原为主;约9 940～2 320 a B P,植被得到进一步发展,气候表现出温暖湿润的特征;约2 320 a B P至今,植被仍以草原为主,气候向温凉方向发展.
基金Supported by National Eye Institute,National Institutes of Health Grant,No.K08-EY021189an Unrestricted Grant from Research to Prevent Blindness+1 种基金A Career Development Award Recipient from the Research to Prevent Blindness Foundation to Dr.SodhiandScholar at the Wilmer Eye Institute to Ryan SJ
文摘By 2050 the prevalence of diabetes will more than triple globally,dramatically increasing the societal and financial burden of this disease worldwide.As a consequence of this growth,it is anticipated that there will be a concurrent rise in the numbers of patients with diabetic macular edema(DME),already among the most common causes of severe vision loss worldwide.Recent available therapies for DME target the secreted cytokine,vascular endothelial growth factor(VEGF).This review focuses on the treatment of DME using the first humanized monoclonal antibody targeting VEGF that has been Food and Drug Administrationapproved for the use in the eye,ranibizumab(Lucentis).
